chevron_leftBack
As of 13 June 2026, Evolus, Inc. has a market cap of $337.01M USD, ranking #17861 globally and #2982 in the United States.
It ranks #1617 in the Healthcare sector, and #582 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$337.01MUSD
Enterprise Value
$434.6MUSD
Revenue (TTM)
$297.18MUSD
EBITDA (TTM)
-$30.09MUSD
Net Income (TTM)
-$51.64MUSD
EBITDA Margin
-10%
Profit Margin
-17%
PS Ratio
1.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
David Moatazedi
open_in_new
Employees
334
Founded
2012
IPO
08 Feb 2018
Website
evolus.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.7% | -0.2% | 29% | 7.9% | -26% | -54% |
News
Loading...
EOLS Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
EOLS
Evolus Inc
ISIN: US30052C1071
Shares Out.:
Shares Outstanding:
65.855M1
Shares Float:
55.541M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
5.18 USD | |
|
0K16
Evolus Inc
ISIN: US30052C1071
|
14.58 GBP |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Evolus, Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
226K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
162K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
107K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
81K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
44K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
35K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
95K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
86K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
81K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
54K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
33K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
32K%
80.96B GBP
|
14.6
|
chevron_leftBack